A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
Phase 2
465
about 1.8 years
18+
18 sites in CA, CO, FL +8
What this study is about
Researchers are testing how well different doses of a new medicine called NNC0519-0130 can reduce kidney damage in people with chronic kidney disease. Participants will receive either NNC0519-0130, semaglutide (a medicine that doctors can already prescribe), or a placebo. The trial will last for up to 43 weeks.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take NNC0519-0130
- 2.Take Placebo
- 3.Take Semaglutide
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
semaglutide (GLP-1 agonist; stimulates insulin release)
oral (Oral Tablet)
Primary: Change in urinary albumin-to-creatinine ratio (UACR) at week 12, Change in urinary albumin-to-creatinine ratio (UACR) at week 24, Change in urinary albumin-to-creatinine ratio (UACR) at week 36
Secondary: Change in diastolic blood pressure, Change in estimated glomerular filtration rate (eGFR) (creatinine and cystatin C-based Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] 2021), Change in estimated glomerular filtration rate (eGFR) (creatinine-based CKD-EPI 2021), Change in glycated haemoglobin (HbA1c), Change in systolic blood pressure, Change in waist circumference, Number of treatment emergent adverse events (TEAEs), Relative change in body weight
Renal